Business
Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche
Atea to lead global clinical trial development of AT-527 and regain ex-US commercial rights BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals,
About this update from Atea Pharmaceuticals, Inc.
[{"type":"text","content":"Atea to lead global clinical trial development of AT-527 and regain ex-US commercial rights\nBOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be returned to Atea, and Atea will have full rights to continue the clinical development and future commercialization of AT-527 worldwide. “We believe strongly in the potential of AT-527 with its unique dual mechanism of action, antiviral activity against the major variants of concern and its market potential given the need for additional therapeutic options for COVID-19,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. “We have the financial resources and the talent to independently drive forward the Phase 3 MORNINGSKY clinical trial program, and we continue to expect data from this trial during the second half of 2022. We are energized by the opportunity to move forward with full ownership, providing us with autonomy to efficiently bring AT-527 to market.” The strategic collaboration with Roche, which included joint development, will be terminated on February 10, 2022. “We are continuing to expedite efforts to submit the recently announced Phase 3 MORNINGSKY amendment to global health authorities,” said Janet Hammond, MD, PhD, Chief Development Officer of Atea Pharmaceuticals. “We have an established development team at Atea with extensive global clinical trial experience, as well as outside resources we continue to leverage. We remain committed to developing and delivering AT-527 as an oral antiviral that will address treatment needs for patients as COVID-19 continues to evolve.” As of September 30, 2021, Atea reported cash and cash equivalents of $839.7 million with a cash runway through 2023. About the AT-527 COVID-19 Clinical Development Program Derived from Atea’s nucleos(t)ide prodrug platform, AT-527 is an oral direct-acting antiviral which is being studied to determine its potential to protect against disease progression and the development of long-COVID complications. Its unique mec...